Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
<p>Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus concomitant and adjuvant temozolomide (TMZ), provides less than 15-month survival benefit. Efforts by conve...
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 出版事項: |
Frontiers Media
2023
|